Alector was officially founded in 2013 by a team of visionary scientists and biotechnology entrepreneurs, including Dr. Arnon Rosenthal, with the core mission of harnessing the immune system to combat severe neurodegenerative disorders. Since its inception, the company has focused heavily on pioneering immuno-neurology research, securing prominent venture capital backing, and establishing strategic alliances with global pharmaceutical giants to advance its therapeutic pipeline.